Company: SUPN
Filing Date: 2025-06-17
Form Type: 8-K
Source: 0001356576-25-000042
Chunk: 0

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 16, 2025 Supernus Pharmaceuticals, Inc. (the “ Company”) held its annual meeting of stockholders (the “ Annual Meeting”). The definitive proxy statement pertaining to the Annual Meeting was previously filed by the Company with the Securities and Exchange Commission on April 30, 2025. As of the close of business on April 22, 2025, there were 55,989,623 shares of common stock outstanding and entitled to vote. The tabulation of votes for each proposal voted on by the stockholders was as follows:

Proposal 1: Election of Class I Directors, each to serve until the Annual Meeting of the Company in 2028.

  Name                               Votes For      Votes Withheld      Broker Non-Votes  
 ──────────────────────────────────────────────────────────────────────────────────────────
  Carolee Barlow, M. D., Ph. D      46,104,993           1,426,932             2,024,865  
  Jack A. Khattar                   46,511,003           1,020,922             2,024,865  

Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers.

   Votes For      Votes Against      Abstain      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────────
  45,796,936          1,701,777       33,212             2,024,865  

Proposal 3: Ratification of the appointment of KPMG LLP as the Company’s independent public accounting firm for the fiscal year ending December 31, 2025.

   Votes For      Votes Against      Abstain      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────────
  49,230,498            310,868       15,424                     0  

Item 9.01 Financial Statements and Exhibits.